Abhishek ("Shake") Kumar, MD MAS
@ShakeKumarMD
Followers
751
Following
7K
Media
136
Statuses
2K
Radiation Oncology Chief Resident @DukeRadOnc | @ARRO_org Executive Committee Vice-Chair
Durham, NC
Joined November 2009
RT @DukeRadOnc: We celebrated Dr. Christopher Willett's two decades of leadership as chair yesterday! We are so grateful for his service, v….
0
4
0
RT @EPotterMD: I’m sharing an actual recent peer-to-peer call that shows what physicians and patients face when trying to get a surgery app….
0
2K
0
RT @chr_huang: New year new PGY2s!! 💙 Let's be awesome educators and promote a supportive work environment. We all have the same goals: gre….
0
4
0
RT @ElliotServaisMD: AIM-HIGH trial published in Lancet.Molecular high-risk stage IA-IIA NSCLC as determined by 14-gene assay with improved….
0
48
0
RT @DukeRadOnc: Duke #RadOnc is so proud of our graduating residents. Thank you to Drs. Acklin-Wehnert, Gooding, Kumar and Leng for their c….
0
2
0
RT @jonas_willmann: ❓ESTRO & EORTC proposed a classification to standardize reirradiation. But does it predict outcomes or toxicity?. 🫁☢️ W….
0
15
0
RT @SuyogCancer: 🌍📚 Calling the global oncology community!.We've launched a WhatsApp Academic Group to share:.🔹 Key trial data.🔹 Conference….
0
17
0
RT @NicholasZaorsky: My 2025 ASTRO GU #radonc spring refresher presentation (+ hidden slides) is available online.#….
0
43
0
RT @DrewMoghanaki: From my perspective, this UPMC phase II study for H&N cancers is a landmark randomized clinical trial, even though it en….
0
7
0
RT @VedangMurthy: During residency, when modems crackled and PubMed barely loaded, I relied on Sem in Rad Oncol for the latest info. Contr….
0
12
0
RT @KamalThippu: 📣#PACE - PACE C trial early toxixity data out now! . 👉
thelancet.com
Despite an accelerated treatment schedule and a larger treated volume than PACE-B, SBRT and MHRT had similar rates of early RTOG toxicity.
0
15
0
RT @MikkaelSekeres: Announcing the first EVER @JCO_ASCO Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉.We're looking for essays that e….
ascopubs.org
0
32
0
RT @VedangMurthy: @jryckman3 @davcmed @DrAndrewLoblaw @cristian_udo @krishnan_patel Looks like we beat you to it Drew! 😀.PSMA-PET, MRI, DIL….
pubmed.ncbi.nlm.nih.gov
Boost volumes on 68Ga-PSMA-PET/CT and mpMRI were volumetrically similar, however, with poor spatial concordance. The %SUVmax threshold for GTVPET contouring correlated inversely with DIL SUVmax and...
0
5
0
RT @DrAndrewLoblaw: I stand corrected! Well done @VedangMurthy . I’m so glad we have the same questions and drive to answer those question….
0
2
0
RT @CJTsaiMDPhD: @DrewMoghanaki @_ShankarSiva @TROGfightcancer This is great and much needed. Congrats on getting this through and funded!.
0
1
0
RT @Erman_Akkus: Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, mul….
thelancet.com
Upfront chemoradiotherapy and three cycles of consolidation FOLFOX result in a high rate of clinical complete response with an acceptable toxicity profile. Total neoadjuvant therapy combined with a...
0
43
0
RT @Sushilberiwal: Finally one positive data on breast cancer for oligoprogression. Focused only on HR positive breast cancer unlike previo….
0
6
0